Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Researchers note many people first hearing of new drugs via social media, increasing the risk of the spread of disinformation ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...